skin cancer
DermTech Stock Soars on News of Additional Coverage for Melanoma Detection Test
The molecular diagnostics firm said two payors with 1.2 million members in New York and Hawaii will cover DermTech's noninvasive testing platform.
Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy
The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.